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Allogeneic cell therapy products have enormous potential to treat a wide range of unmet medical needs, with 
various drug candidates getting closer to commercialization. However, the limited manufacturing capacity of 2D 
planar technology to meet commercial demands could be a potential bottleneck for the future success of the 
emerging cell therapy industry.  With the benefits of high volumetric productivity, operational controllability, and 
scalability of cell culture processes for therapeutic protein manufacturing, single-use bioreactors are recognized 
as promising solutions for large-scale manufacturing of cell therapy products. However, cell therapy products 
have unique bioprocessing requirements that are different from protein manufacturing.  Not only is the final 
product the cell itself, but many cell therapy products are anchorage-dependent and grow on microcarriers or as 
cell aggregates. These microcarriers and cell aggregates are much larger than free-floating single cells and 
require comparatively greater power input to be suspended in a bioreactor, which can lead to hydrodynamic 
sheer stress and damage to cells. While various cell types require different bioreactor processes, a single-use 
bioreactor with the following capabilities would be greatly beneficial for reliable scale up of cell therapy 
manufacturing. One capability is to homogeneously and efficiently suspend large particles in a low shear 
environment. Another is to provide evenly distributed dissipation energy inside the vessel, leading to uniform 
aggregate size formation. Finally, both of these capabilities should be reproducible at larger volumes so that 
micro-environments inside the bioreactors are consistent across various working volumes.  
 
A novel, single-use Vertical-Wheel bioreactor system was designed and introduced in an attempt to provide 
these capabilities. Experiments with various cell types such as human mesenchymal stem cells (MSCs), 
embryonic stem cells (ESCs), pluripotent stem cells (PSCs), and chondrocytes have been performed in different 
sizes of Vertical-Wheel bioreactors with the following results. Comparable cell growth of MSCs (550,000 to 
600,000 cells/mL on day 5) in a xeno-free microcarrier culture was achieved in three different scales of 
bioreactors (0.1L, 3L, and 15L). After the cell expansion phase, in-vessel cell dissociation from microcarriers 
using Trypsin was performed in the 15L Vertical-Wheel bioreactors with a greater than 90% harvest yield. 
Aggregates of ESCs grown in 0.5L Vertical-Wheel bioreactors were shown to be more uniform in size compared 
to aggregates grown in stirred-type spinner flasks. Furthermore, the narrow range of aggregate sizes (150-250 
microns) after three days of cultivation in 0.5L Vertical-Wheel bioreactors was reproduced at larger 3L scale. 
The size of PSC aggregates could also be controlled by adjusting agitation rate, with higher speeds resulting in 
smaller aggregates and lower speeds in larger aggregates. In addition, pluripotency of PSC aggregates was 
maintained after cell expansion, as indicated by specific surface marker identifiers. Directed differentiation of 
PSCs in a single-use bioreactor is another important challenge of manufacturing scale up. Vertical-Wheel 
bioreactors have been used to successfully differentiate PSCs into different types of target cells, such as insulin-
producing SC-islets or cerebellar organoids. 
 
In order for single-use bioreactors to become the standard manufacturing platform for cell therapy products, an 
ideal bioreactor system should be able to deliver highly productive, reliable, and reproducible cell culture 
performance at commercial scale. Further details regarding manufacturing challenges and experimental data 
will be discussed in this presentation.  
 
